The practice existed in a regulatory gray zone but was not actively prohibited
The addition of lixisenatide to standard therapy did not significantly alter the rates of CV events or hospitalizations in high-risk patients, although it did result in modest but significant reductions in A1c, weight, and systolic BP compared to standard therapy
10.1292/jvms.70.739 3
The combination of GLP-1 and glucagon agonism increased energy expenditure through thermogenic activation in brown adipose tissue
Human hepatic 3D spheroids as a model for steatosis and insulin resistance
Clarke BA, Drujan D, Willis MS, Murphy LO, Corpina RA, Burova E, Rakhilin SV, Stitt TN, Patterson C, Latres E, Glass DJ (2007) The E3 Ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle